|
|
||||||||
Ann Thorac Surg 2006;82:268-273
© 2006 The Society of Thoracic Surgeons
a Division of Thoracic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
b Center for Clinical Effectiveness in Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
c Policy Analysis, Inc, Brookline, Massachusetts
Accepted for publication January 17, 2006.
* Address correspondence to Dr Gaissert, Massachusetts General Hospital, Blake 1570, 55 Fruit St, Boston, MA 02114 (Email: hgaissert{at}partners.org).
Presented at the Forty-second Annual Meeting of The Society of Thoracic Surgeons, Chicago, IL, Jan 30Feb 1, 2006.
| Abstract |
|---|
|
|
|---|
METHODS: A retrospective analysis was performed of uncommon tracheal tumors among 360 primary tracheal tumors seen over 40 years, excluding adenoid cystic and squamous cell carcinoma.
RESULTS: Of 90 patients, 34 (38%) had benign tumors and 56 malignant: 11 carcinoid tumors, 14 mucoepidermoid carcinomas, 13 sarcomas, 15 nonsquamous bronchogenic carcinomas, 2 lymphomas, and 1 melanoma. Three patients had a second tracheal malignancy. Dyspnea was the most common symptom in benign tumors and hemoptysis in malignant tumors. Twelve patients did not undergo tracheal resection (13.3%) and 1 died before resection. Surgical therapy in 77 patients (85%) consisted of laryngectomy in 3, laryngotracheal resection in 9, tracheal resection in 46, and carinal resection in 19. Hospital mortality was 2.6% (2 of 77 patients) and major complications occurred in 16% (12 of 77 patients). Mean follow-up was 9.7 years. After resection, survival at 10 years was 94% for benign and 83% for carcinoid tumors, and at 5 years survival was 60% for bronchogenic carcinoma, 100% for mucoepidermoid tumors, and 78% for sarcomas. Patients with lymphomas and melanoma are alive more than 8 years after resection. Ten patients experienced recurrence (14%).
CONCLUSIONS: Surgical resection of uncommon primary tracheal tumors alleviates airway obstruction, is curative in patients with benign or slow-growing malignant lesions, and prolongs survival in highly malignant lesions.
| Introduction |
|---|
|
|
|---|
| Patients and Methods |
|---|
|
|
|---|
Determination of Resectability
Every patient underwent rigid bronchoscopy. Bronchoscopic biopsy was performed of any lesion deemed malignant and selectively of those that were localized and apparently benign. Patients with malignant tumors also had an assessment of locoregional and distant metastatic disease before resection. The most striking change in the preoperative radiographic evaluation over 40 years has occurred with the shift from conventional tracheal tomography to computed tomography and its recent algorithms for three-dimensional depiction of the tracheal lumen. An improved yield of information that would affect the determination of resectability or a decreased need for exploration has not yet been identified. Tracheal resection was considered only when complete resection seemed feasible. Microscopic involvement of airway margins was accepted if the airway was normal on gross inspection and no further length of airway could be resected. Resection was not performed when it would have resulted in grossly positive peritracheal margins. A tumor was also considered unresectable when metastatic disease was present, the length of involved airway at bronchoscopy was judged to preclude safe reconstruction, or invasion of certain adjacent organs was found during operative exploration. Local resection of esophageal invasion with lateral excision of muscle or full-thickness esophageal wall was considered, but total esophagectomy was not performed to avoid devascularizing the trachea.
Types of Resection
The surgical technique has been detailed previously [9]. For standard tracheal resection, a sleeve of trachea is removed with end-to-end reconstruction. When laryngectomy is required, cervical or mediastinal end-tracheostomy is performed. For laryngotracheal resection, the tumor-bearing infraglottic larynx is removed while preserving at least one recurrent laryngeal nerve. A purely bronchoscopic resection is considered in patients with multiple mucosal tumors that cannot be encompassed with a segmental tracheal resection.
In malignant tumors, systematic lymph node dissection is avoided to preserve tracheal blood supply. Regional lymph nodes are often not included in the specimen if not grossly enlarged. Absence of tumor at the airway margins is confirmed by frozen section unless the limits of resection have been reached and no additional trachea can be removed. The resection is judged to be complete when airway margins are found to be disease-free, the peripheral soft tissue margin does not expose gross tumor, and no statement in the operative note indicates that the resection was incomplete.
Tumor Data
Tumor dimension in the long axis of the airway, depth of invasion, and the presence of tumor at airway or radial margins were recorded after resection from a review of pathology reports. Positive airway margins indicated true residual tumor, most often microscopic. In contrast, the radial margins were interpreted as positive when tumor was seen within 1 mm of the margin, usually indicating that only a thin layer of connective tissue covered the outside of the tumor. Tumor involvement of excised lymph nodes was noted.
Adjuvant and Primary Radiotherapy
Adjuvant postoperative radiotherapy was introduced for malignant tumors during the second decade of this experience for close or tumor-bearing margins. After bronchoscopic assessment of anastomotic healing, a recommended dose of 54 Gy was administered 6 weeks after resection. Primary radiotherapy with 60 Gy was recommended for patients who had unresectable tumors, but could not be confirmed in all patients. Most patients received radiation treatment outside Massachusetts General Hospital.
Follow-Up
Patients and their physicians were contacted for follow-up information. The Social Security Death Index was searched. Patients were determined to have died if name, date of birth, and social security number matched. Follow-up information on treatment and tumor status in patients who did not undergo resection was often limited to the date of death.
Statistical Analysis
Crude (arithmetic) survival rates were calculated for tumor type and resection, whereas adjusted (KaplanMeier) survival rates were selected for benign and malignant tumors using the SAS system (SAS, version 9.13, Cary, NC).
| Results |
|---|
|
|
|---|
|
|
Seventy-seven patients underwent segmental resection of the tumor. These procedures were the first attempt at tracheal resection except in 2 patients who had prior interventions elsewhere: 1 had a local excision of the cervical tracheal wall through which a tracheostomy had been placed. The other had a tracheal resection for adenocarcinoma and was referred with a positive resection margin. The resection rate for benign tumors was 96%, excluding squamous papillomas. For malignant tumors, the resection rate was 89%. The types of procedures are detailed in Table 3. A majority of resections, 60%, involved tracheal end-to-end reconstruction. One tracheal resection for a recurrent plexiform neurofibroma included lateral full-thickness resection of the esophageal wall.
|
|
Postoperative radiation was administered to 18 patients with malignant tumors. Fifteen patients received more than 45 Gy and 3 patients received 45 Gy or less.
Follow-Up
Mean follow-up was 9.7 ± 8.3 years. Follow-up was 84% complete. Resection was associated with improved survival. The rate of survival at 1, 5, and 10 years was 96%, 87%, and 75%, respectively, in patients undergoing resection and 73%, 30%, and 12%, respectively, without resection. As demonstrated in Table 5, benign tumors and low-grade malignancies had comparable long-term outcome, whereas high-grade malignant tumors demonstrated marked attrition of survival after resection and no long-term survivors without resection. Figure 1
depicts the survival curve of benign and malignant tumors.
|
|
| Comment |
|---|
|
|
|---|
Surgical resection should be offered to patients with benign tumors. As newer techniques for local tumor destruction become available, these will without doubt be applied to tracheal tumors, as have cryoablation [11], photodynamic therapy [12], laser [13], and brachytherapy [14]. Because these alternatives focus on restoring the airway lumen, rather than on complete resection, they should be reserved for isolated mucosal lesions in multiple sites, notably squamous papillomas. Most tumors, however, grow into or through the tracheal wall and can therefore not be completely excised by endoscopic techniques. Surgical risk cannot serve as justification for incomplete endoscopic resection even in benign tumors; medical contraindications did not preclude resection in any of our patients. Complete resection is compromised only by excessive length of tumor or extensive radial growth into adjacent soft tissue and organs. Carinal resection in malignant tumors continues to have a higher risk than standard tracheal procedures and remains a challenge when tumor length increases tension on the remaining airway. In all other patients, segmental airway resection for uncommon tracheal tumors is a low-risk procedure [9].
| Discussion |
|---|
|
|
|---|
DR GAISSERT: We found squamous papilloma in multiple locations in 5 patients and in a solitary location in 4 patients and these 4 patients underwent resection, and so far we have not seen recurrences. We have treated multiple locations with laser, in a similar manner as you did, but all solitary lesion we have resected with good results.
DR KORST: Excellent. Thank you.
DR THOMAS J. WATSON (Rochester, NY): Henning, I really enjoyed the talk. Along similar lines, I'm a bit curious about your recommendation for resection of benign lesions. You reported on a number of benign lesions that were not resected, yet with 100% 10-year survival. And your last point was that alternative treatments, other than resection, must show equal or better results. I would argue that for benign lesions, non-resectional therapies yielded results that were equal or better. Can you comment on that, please?
DR GAISSERT: In benign tumors you still have the issue of airway obstruction, so the question is how do you deal with airway obstruction. You can locally destroy the tumor, but then you leave a tumor behind and you need to follow the tumor. The alternative is to resect the lesion and obviate further follow-up if you have performed a complete resection.
DR ROBERT J. CERFOLIO (Birmingham, AL): Just a quick question about the chin stitch. I know youR group has written to leave that in 7 or 8 days. We've used this as well, but have only left it for in place, if there is not much anastomotic tension for only 3 or 4 days. Have you shortened your time for the chin stitch, any tricks to having your patients and more importantly their family members tolerate it, and do you still use 7 days? Thanks.
DR GAISSERT: The chin stitch was not part of our database, so I cannot comment on the use in these patients. But it is meant to prevent neck extension. It is not meant to attach the chin to the chest. That would have rather deleterious results. I cannot recommend that at all. It is fairly well tolerated if it just prevents extension, and then we use it in any tracheal resection; however, usually not in carinal resection unless larger segments of trachea are resected at the same time. We have somewhat different practices, but these chin stitches stay in for about 6 to 7 days.
DR REZA J. MEHRAN (Houston, TX): I have one question about the slow-growing adenoid cystic carcinoma. Patients in your group with this histology with locoregional disease, meaning N2 disease, how did you treat them; neoadjuvant treatment followed by resection, resection followed by adjuvant treatment, or no resection at all? Thank you.
DR GAISSERT: This is an experience that extends over about 40 years, so there are patients with node-positive adenoid cystic carcinoma that we didn't know about before the operation, and we do not perform a radical lymphadenectomy as part of the procedure because we are concerned about the blood supply of the trachea. In a separate review of our experience in adenoid cystic carcinomas, we could not show a clear relationship between node-positive results and worse survival. We suspect that that is the case, and if we would find an adenoid cystic carcinoma with extensive lymphadenopathy, we would probably not operate. We would regard that as extensive regional disease and not operate.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
T. Krajc, M. Janik, R. Benej, M. Lucenic, I. Majer, J. Demian, and S. Harustiak Urgent segmental resection as the primary strategy in management of benign tracheal stenosis. A single center experience in 164 consecutive cases Interactive CardioVascular and Thoracic Surgery, December 1, 2009; 9(6): 983 - 989. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Cordos, C. Bolca, C. Paleru, R. Posea, and R. Stoica Sixty tracheal resections - single center experience Interactive CardioVascular and Thoracic Surgery, January 1, 2009; 8(1): 62 - 65. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Terra, H. Minamoto, J. J.M. Junqueira, R. Falzoni, P. M. Pego-Fernandes, and F. B. Jatene Tracheal Malignant Melanoma: Successful Outcome With Tracheal Resection Ann. Thorac. Surg., July 1, 2008; 86(1): 308 - 310. [Abstract] [Full Text] [PDF] |
||||
![]() |
S JAIN, J P AGARWAL, T GUPTA, P M PARIKH, R C MISTRY, H MENON, C S PRAMESH, and S K SHRIVASTAVA Second primary small cell carcinoma of the trachea in a breast cancer survivor: a case report and literature review Br. J. Radiol., April 1, 2008; 81(964): e120 - e122. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. E. Haver, C. J. Hartnick, D. P. Ryan, R. Shailam, and E. J. Mark Case 10-2008 -- A 10-Year-Old Girl with Dyspnea on Exertion N. Engl. J. Med., March 27, 2008; 358(13): 1382 - 1390. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |